Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population

Alemayehu, Berhanu; Buysman, Erin; Parry, David; Becker, Laura; Nathan, Faith E.

doi:10.3111/13696998.2010.491435

Cited by 47 publications

(45 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 20 The prevalence CRPC has been estimated to be 17.8% among patients with prostate cancer. 15 A simulated model used data from several large clinical trials to estimate the epidemiology of various prostate cancer disease states and projected the incidence and prevalence of metastatic CRPC in the United States in 2020 to be 43 211 and 76 431 cases respectively. 21 Such simulated models may be useful in clinical research and healthcare policy by forecasting the projected effect of a new drug on the incidence and prevalence of CRPC.…”

Section: Incidence and Prevalencementioning

confidence: 99%

“…We also included data and references from peer reviewed organizational guidelines (American Urological Association (AUA), European Association of Urology (EUA), and National Comprehensive Cancer Network (NCCN)). [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] We used www.clinicaltrials.gov to find active clinical trials relevant to the section on "emerging therapies. "…”

Section: Sources and Selection Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Advances in the management of castration resistant prostate cancer

Ritch

Cookson

2016

BMJ

View full text Add to dashboard Cite

Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab). Given that docetaxel was the standard first line treatment for metastatic CRPC, the newer oral agents that affect the androgen axis were initially approved in the post-docetaxel setting. However, subsequent randomized trials have led to their approval in the pre-chemotherapy setting as well. Patients with CRPC are clinically heterogeneous, ranging from patients who are asymptomatic and do not have metastases to those with substantial symptoms and both bony and visceral metastases. CRPC is a clinically challenging disease entity, therefore, with a wide array of treatment options and multiple possible sequencing combinations depending on the individual patient. This review will summarize the findings of the randomized trials that led to the approval of the therapies for CRPC. It will also discuss recent guidelines and provide suggestions for sequencing of drugs based on the best available evidence.

show abstract

Section: Incidence and Prevalencementioning

confidence: 99%

Section: Sources and Selection Criteriamentioning

confidence: 99%

Advances in the management of castration resistant prostate cancer

Ritch

Cookson

2016

BMJ

View full text Add to dashboard Cite

show abstract

“…At the time of diagnosis, 84% of men with CRPC exhibit metastases and another 5% will develop metastatic disease within 2 years after the diagnosis [2]. Until recently, the median survival after diagnosis of CRPC was only 14 months.…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 1 in 9 men will develop PCA during their lifetime. In 2008, about 899,000 cases with PCA have been diagnosed worldwide and about 50% of these men will develop metastatic disease within the 5-10 years of follow-up, and approximately 10-20% of those will develop castration-resistant PCA (CRPC) within 5 years of follow-up [2]. …”

Section: Introductionmentioning

confidence: 99%

The Role of Palliative Surgery in Castration-Resistant Prostate Cancer

Heidenreich

Porres²,

Pfister³

2015

Oncol Res Treat

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) analogues or antagonists represents the treatment of choice in men with metastatic prostate cancer (PCA). Depending on the serum concentration of the prostate-specific antigen (PSA) nadir, the survival might vary between 11 and 78 months. In castration-resistant PCA (CRPC), all new medical treatment options can induce complete and partial remissions in metastatic foci, but they have no profound effect on the prostate itself, as has been shown recently. About one-third of all patients without local treatment of the primary will develop significant complications of the lower and upper urinary tract due to local progression of the PCA. In men with CRPC and lower urinary tract symptoms, palliative transurethral resection of the prostate (TURP) can be performed with a 60-70% success rate. Infiltration of the pelvic floor, the bladder neck and trigone, and the external urethral sphincter can make palliative radical surgery necessary. Bladder neck closure with continent vesicostomy, radical cystoprostatectomy with an incontinent urinary diversion, and anterior and posterior exenteration are individual therapeutic options in men with a good performance status and a considerable life expectancy. Symptomatic involvement of the upper urinary tract can be managed by the placement of endoluminal stents or a percutaneous nephrostomy in men with poor performance. In men with a good response to ADT and a good performance status, reconstructive ureteral surgery might be considered and the options of ureteral reimplantation, ureter ileal replacement, and a subcutaneous pyelovesical bypass have to be discussed. The indication to perform one of the above-mentioned surgical approaches needs to be discussed in a multidisciplinary tumor board.

show abstract

“…About 1 in 9 men will develop prostate cancer during their lifetime, and in 2012, 1,094,916 new cases were diagnosed worldwide [4]. 10-20% of all patients will develop castration-resistant prostate cancer (CRPC) within 5 years of follow-up [5]. Approximately 84% of men with CRPC will present with metastatic disease at the time of diagnosis, and another 5% will develop metastatic disease within 2 years of being diagnosed with CRPC [6,7].…”

Section: Introductionmentioning

confidence: 99%

Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine

Herden

Heidegger²,

Paffenholz³

et al. 2015

Oncol Res Treat

View full text Add to dashboard Cite

The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and biological aggressiveness of the disease. Furthermore, treatment-associated side effects differ between the various drugs. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. It is the aim of the current article to i) summarize the data of established treatment options in mCRPC, ii) highlight new developments in medical treatment, iii) provide clinically useful algorithms for the daily routine, and iv) point out future developments in medical treatment.

show abstract

Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population

Abstract: CRPC is a costly disease, with ambulatory visits and inpatient care accounting for a substantial proportion of the economic burden. Limitations related to the use of retrospective claims data should be considered when interpreting these results.

Cited by 47 publications

References 17 publications

Advances in the management of castration resistant prostate cancer

Advances in the management of castration resistant prostate cancer

The Role of Palliative Surgery in Castration-Resistant Prostate Cancer

Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine

Contact Info

Product

Resources

About